KROS
Keros Therapeutics Inc
11.20$
+1.8%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -424,775.0% | -17,803.5% | -53,686.7% | -107,570.3% | -7,860.8% | -1,512.4% | 76.3% | -163.1% | 22.8% | -7,088.8% | -961.6% | -112.4% | -144.6% | |
| 2,625.0% | 172.7% | 333.7% | 827.0% | 80.9% | 10.9% | 0.2% | 2.0% | 2.8% | 103.9% | 109.8% | 2.2% | 4.8% | |
| 108,887.5% | 5,121.7% | 9,722.9% | 23,743.2% | 2,272.4% | 302.4% | 4.2% | 47.0% | 27.9% | 1,897.4% | 1,689.1% | 29.6% | 68.9% | |
| -47,550.0% | 4,809.8% | -12,207.2% | -10,759.5% | 3,289.2% | -331.6% | 1.4% | -46.3% | 38.8% | -3,158.2% | 3,526.2% | 10.2% | 24.6% | |
| 6,875.0% | 378.3% | 1,139.8% | 837.8% | 99.5% | 9.5% | 0.3% | 4.0% | 0.9% | 34.8% | 19.9% | 0.9% | 1.5% | |
| -6,875.0% | -378.3% | -1,139.8% | -837.8% | -99.5% | -9.5% | -0.3% | -4.0% | -0.9% | -34.8% | -19.9% | -0.9% | -1.5% | |
| – | – | – | – | – | – | – | – | 1.0% | – | – | – | – | |
| 3,550.0% | 48,429.4% | 188,918.1% | 9,543.2% | 40,191.8% | 2,483.4% | 0.0% | 0.1% | 1.0% | -98,345.7% | -631.1% | -18.2% | -1,157.6% | |
| -426,662.5% | 30,247.6% | 134,091.6% | -98,864.9% | 32,231.4% | 961.4% | 76.0% | -166.9% | 22.8% | -105,469.4% | -1,612.5% | -131.5% | -1,303.7% | |
| -431,650.0% | -18,181.8% | -54,826.5% | -108,408.1% | -7,960.3% | -1,521.9% | 76.0% | -167.0% | 21.9% | -7,123.6% | -981.5% | -113.3% | -146.1% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.